Dupixent® Lawsuit

Dupixent (generic name dupilumab) is a biologic drug jointly developed by manufacturers Sanofi and Regeneron. It was first approved by the FDA in 2017 to treat moderate-to-severe atopic dermatitis, more commonly known as eczema. Since then, its approved uses have expanded to include:

• Asthma (particularly eosinophilic or oral-steroid dependent forms)
• Bullous pemphigoid (BP)
• Chronic obstructive pulmonary disease (COPD)
• Chronic rhinosinusitis with nasal polyps
• Chronic spontaneous urticaria (CSU)
• Eosinophilic esophagitis
• Prurigo nodularis

The drug works by blocking two pathways involved in signaling (starting and growing) inflammation, interleukin-4 (IL-4) and interleukin-13 (IL-13). By dampening this immune response, Dupixent helps reduce itching, skin lesions, breathing difficulty and nasal polyps.

Sanofi and Regeneron have marketed Dupixent as a safer long-term therapy compared to systemic steroids or immunosuppressants. But recent research has connected the drug to a rare cancer. Dupixent lawsuits are in the beginning stages. The lawsuits will allege the companies minimized or ignored warning signals related to rare but severe diseases such as cancer.

While Dupixent has helped many patients achieve relief from severe eczema and asthma, mounting evidence shows that it may also carry severe and underreported risks. Dupixent has allegedly been linked to serious cancer risk. One alarming safety concern involves a potential link to cutaneous T-cell lymphoma (CTCL). This is a rare and aggressive type of non-Hodgkin lymphoma that primarily affects the skin. There are also subtypes of CTCL called Sezary Syndrome and mycosis fungoides.

CTCL symptoms include:

• Bumps on the skin that might break open
• Hair loss
• Rash-like discoloration all over the body that may become raised, flaky or itchy
• Swollen lymph nodes
• Thickened skin on the palms of hands and the soles of feet

Common side effects of Dupixent not involved in lawsuits include eye inflammation and conjunctivitis, injection site reactions, eosinophilia (abnormally high white blood cell counts) and joint pain.

Recent research flags Dupixent cancer risks

A 2024 study published in the Journal of the American Academy of Dermatology compared CTCL risk in people who did and did not use Dupixent. Researchers found that patients with atopic dermatitis who used Dupixent had a 4.1-fold higher risk of developing CTCL compared to those who did not. In most cases, the cancer was diagnosed more than a year after treatment with Dupixent began.

A 2025 analysis published in the Journal of Allergy and Clinical Immunology built on these findings. The study examined U.S. Food and Drug Administration (FDA) safety data. Researchers found that Dupixent users reported CTCL 30 times more than those using all other medications. The study also suggested that dupilumab may alter IL-4 and IL-13 receptor pathways. This change could potentially accelerate CTCL development in susceptible patients.

Who can file a Dupixent lawsuit?

Patients and families may qualify to file a Dupixent lawsuit if they meet certain criteria. You may be eligible for a Dupixent claim if you:

• Were prescribed and took Dupixent for eczema, asthma or other approved uses
• Were diagnosed with cutaneous T-cell lymphoma (CTCL) after taking Dupixent
• Lost a loved one to CTCL after they took Dupixent

Timing matters. In many reports, CTCL was diagnosed more than a year after Dupixent treatment began. This suggests that the drug may accelerate or unmask disease in certain patients. Filing deadlines also vary by state. It’s important to contact a lawyer experienced in injuries related to prescription medicines as soon as possible to evaluate your legal options.

Is there a Dupixent class action lawsuit?

Currently, Dupixent claims  are in the early stages of investigation. There is currently no class action or multidistrict litigation (MDL). The number of future filings, if any, will dictate whether the parties move for an MDL.

What compensation may be available in a Dupixent lawsuit?

Compensation may include coverage for medical bills, lost wages, pain and suffering and loss of quality of life. Wrongful death damages for surviving family members of deceased patients may be available.

How long do I have to file a Dupixent lawsuit?

The deadline to file, known as the statute of limitations (SOL), varies by state. Many states allow two to three years from the date of diagnosis or discovery of harm. Be sure to consult with an attorney as soon as possible to avoid issues.

Has the FDA issued a Dupixent cancer warning?

As of now, the FDA has not added a specific cancer warning to Dupixent’s label. However, adverse event reports and new research are under review, which may influence future label changes.

What should I do if I develop cancer after taking Dupixent?

If you develop cancer or any other serious condition after taking Dupixent, seek immediate medical care. Then, contact a lawyer with experience in pharmaceutical litigation to explore whether you qualify for a Dupixent lawsuit.

If you or a loved one developed cutaneous T-cell lymphoma or other severe side effects after using Dupixent, you may be eligible to file a lawsuit seeking compensation. Motley Rice has a proven track record in complex drug injury litigation. We currently represent clients in cases for serious side effects caused by medications including weight loss drugs, Depo-Provera®, Oxbryta® and Zinbryta®. Our team of drug injury lawyers can help you understand your rights and take the next step toward justice.

We understand the potential pain, serious side effects and health problems allegedly defective drugs can have on you. When you are harmed, so is your family. We approach each case as a unique situation and will work with you to help you understand the often complex legal and scientific aspects involved in medical litigation.

If drugs or medical devices intended to help you or a loved one made you sick, our team can help by:

• Identifying potentially harmful medicines and devices
• Investigating whether the medicine is linked to your illness or injury
• Reviewing the manufacturer’s compliance with FDA regulations
• Examining whether the manufacturer's warning to you about potential side effects was adequate
• Identifying other issues that could affect your potential claim
• Uncovering potential manufacturing defects or issues with the manufacturing process
• Reviewing the applicable statute of limitations

Read more about our drug injury litigation experience.

NOTE: Do not stop taking a prescribed medication without first consulting with your doctor. Discontinuing a prescribed medication without your doctor’s advice can result in injury or death. Dupixent, Depo-Provera, Oxbryta and Zinbryta remain approved by the U.S. Food and Drug Administration.